ReviewEndocrine oncology (Bristol, England)2026
A contemporary overview of multiple endocrine neoplasia syndromes: MEN syndromes 1-5 and beyond.
Review in Endocrine oncology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple endocrine neoplasia (MEN) syndromes constitute a heterogeneous group of hereditary disorders predisposing to endocrine tumours of varying malignant potential. Recent advances in molecular genetics and tumour biology have significantly reshaped our understanding of underlying pathophysiology, enabling earlier diagnosis, genotype-specific surveillance and the emergence of targeted therapies. This review provides a contemporary overview of key recent advances and consensus guidelines across MEN syndromes, including MEN1, MEN2, MEN4, and MEN5 syndromes, SDHx syndrome, Carney complex, McCune-Albright syndrome, DICER1 syndrome and von Hippel-Lindau syndrome. These insights reflect a rapidly evolving field with genetic diagnosis at the centre of prognostic assessment, targeted surveillance and individualised management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.